文献速递类风湿关节炎其他结缔组织病

优化疾病控制与糖皮质激素剂量对风湿病患者骨骼保护均至关重要

Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease.
PubMed 文献 · Ann Rheum Dis · 2022-08-11

Rh-GIOP前瞻性观察队列分析1066例炎症性风湿与骨骼肌肉疾病(iRMD)患者基线数据,发现泼尼松等效剂量≤5 mg/天、累积剂量及疗程与骨密度(BMD)无负相关;类风湿关节炎(RA)中>7.5 mg/天仅在疾病活动度中高(DAS28-CRP>3.2)时与BMD负相关。

要点

  • iRMD患者泼尼松等效剂量≤5 mg/天未显示与BMD降低相关。
  • RA患者GC剂量>7.5 mg/天仅在中高疾病活动度时与BMD负相关。
  • 控制疾病活动可能减轻GC对骨密度的影响。

核心结论

  • iRMD患者泼尼松等效剂量≤5 mg/天似乎与BMD降低无关,可能因GC抑制炎症而减轻骨质疏松风险。
  • RA患者当前GC剂量>7.5 mg/天与BMD负相关,但仅见于疾病活动度中高(DAS28-CRP>3.2)者。

研究设计与样本

  • Rh-GIOP为前瞻性观察队列研究,纳入连续iRMD且当前或既往接受GC治疗的患者,本文分析基线数据。
  • 共分析1066例患者,主要结局为双能X线吸收法测量的骨密度(BMD),采用多因素线性回归识别与BMD相关的变量。

主要发现

  • 泼尼松等效剂量<5 mg/天、累积剂量及GC疗程与BMD无负相关。
  • 泼尼松等效剂量≥5 mg/天在混杂因素校正后与BMD的负相关消失;剂量恰为5 mg/天的亚组分析未见负效应。
  • RA患者GC剂量>7.5 mg/天总体上与BMD负相关,但该效应似乎仅见于疾病活动度中高(DAS28-CRP>3.2)者。

关键数值与推荐

  • 泼尼松等效剂量≤5 mg/天:未显示与BMD降低相关。
  • 泼尼松等效剂量≥5 mg/天:校正混杂后与BMD的负相关消失。
  • RA患者GC剂量>7.5 mg/天:总体与BMD负相关,仅见于DAS28-CRP>3.2者。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Inflammatory rheumatic and musculoskeletal diseases (iRMDs) are associated with increased systemic bone loss that is mediated by chronic inflammation, treatment with glucocorticoids (GCs) and other factors. Our objective was to analyse the impact of variables that influence osteoporosis (OP) in patients with iRMD treated with GC. METHODS: Rh-GIOP (acronyme) is a prospective observational cohort study investigating bone health in consecutive patients with iRMD and current or prior GC treatment. We present an analysis of the patients' baseline data here. Bone mineral density (BMD) measured by dual X-ray absorptiometry was the primary outcome. Multivariable linear regression models were performed to identify variables associated with BMD. RESULTS: Data from 1066 patients with iRMD were analysed. GC doses of <5 mg prednisone equivalent per day, cumulative dose and duration of GC therapy were not associated with negative effects on BMD. Dosages of ≥5 mg/day lost their negative association with BMD after adjustment for confounders. When subanalysing patients with exactly 5 mg/day, no negative effect was seen. For patients with rheumatoid arthritis (RA), GC doses of >7.5 mg/day showed a negative association with BMD overall, but this effect seemed to be specific only to patients with moderate or high disease activity (Disease Activity Score 28-C reactive protein >3.2). CONCLUSIONS: GCs of ≤5 mg/day did not seem to be associated with a reduction of BMD in patients with iRMD and current or prior exposure to GC. This is most likely due to the dampening of inflammation by GC, which exerts a mitigating effect on the risk of OP. In RA, current GC doses of >7.5 mg/day were negatively associated with BMD, but only in patients with moderate to high disease activity. TRIAL REGISTRATION NUMBER: NCT02719314.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Wiebe E, Huscher D, Schaumburg D, et al. Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease. Ann Rheum Dis. 2022. PMID: 35680387. doi:10.1136/annrheumdis-2022-222339

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。